Skip to main content
Equibles
ARWR logo

ARWR · Arrowhead Pharmaceuticals, Inc. · Metrics

Track ARWR — free

Use ARWR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARWR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$58.36 -0.48 (-0.82%)
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$8.15B
Shares
141.25M
Volume · Oct 22 1.04M Avg daily vol (3M) 1.87M

ARWR metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$58.84
Market cap
$8.15B

Price action

20 metrics
Price change (1W)
+0.8%
Price change (30D)
-18.1%
Price change (3M)
-33.7%
Price change (6M)
-20.4%
Price change (YTD)
-11.4%
Price change (1Y)
+54.7%
Trailing year
Price change (5Y)
-12.0%
52-week high
$89.59
52-week low
$37.35
Change from 52-week high
-34.3%
Change from 52-week low
+57.5%
Annualized volatility
61.9%
Annualized volatility (3M)
58.9%
Beta
1.6
RSI (14D)
34.6
Price vs SMA 50
-20.2%
Price vs SMA 200
-18.2%
Avg volume (3M)
1.87M
Relative volume
0.7
Average dollar volume
$139.84M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
141.25M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.2×
reciprocal yield 8.2%
P / book
17.5
reciprocal yield 5.7%
FCF yield
-0.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
—
Operating margin
-33.8%
Trailing 12 months
Net margin
-47.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$226.44M
Net income (TTM)
−$315.24M
Trailing 12 months
Diluted EPS (TTM)
$-2.18
FCF margin
-11.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.79
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.57
EBITDA per diluted share (TTM)
$-1.39
Net income per diluted share (TTM)
$-2.21
Operating cash flow per diluted share (TTM)
$-0.40
Free cash flow per diluted share (TTM)
$-0.51
Capital expenditures per diluted share (TTM)
$0.11
R&D per diluted share (TTM)
$5.14
Stock compensation per diluted share (TTM)
$0.50
Book value per share
$3.43

Growth

11 metrics
Revenue growth YoY
+171.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$669.50M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
+50.5%
Revenue CAGR (5Y)
+56.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-67.7%
Return on assets
-14.9%
Debt / equity
—
Current ratio
5.9
EBITDA (TTM)
−$202.34M
Free cash flow (TTM)
−$75.11M
Quick ratio
5.9
Interest coverage
-2.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$54.76M
Latest balance sheet
Cash & equivalents
$54.76M
Total assets
$2.11B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$59.05M
Capital expenditures (TTM)
$16.06M
R&D (TTM)
$723.37M
SG&A (TTM)
—
Stock compensation (TTM)
$70.00M
R&D / revenue
108.0%
Stock compensation / revenue
10.5%

Ownership (13F)

9 metrics
13F filers
509
13F filer change QoQ
+64
Institutional ownership
86.3%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
27.9%
Private-fund adviser ownership
26.2%
Active holders' share change QoQ
+0.9%
Holder tenure
13.0
Price vs estimated holder cost
+73.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.1%

Short interest

3 metrics
Short interest
7.6%
Latest settlement · 4.0 days to cover
Days to cover
4.0d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.19M
Insider-sentiment score
33 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 879407 CUSIP 04280A100 13F (30d) 59 filings 59 filers Visit website Investor relations